Trial
NCT05634525
Phase Ib Trial of the KRASG12C Inhibitor Adagrasib (MRTX849) in KRAS G12C Mutant Metastatic Pancreatic Cancer Patients
Phase IWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
M.D. Anderson Cancer Center
Collaborators
Mirati Therapeutics Inc.
Condition
Metastatic Pancreatic Cancer
Intervention
MRTX849
Why stopped
No participants enrolled
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-07-25